Xanthone analogues as potent modulators of intestinal P-glycoprotein

European Journal of Medicinal Chemistry

Volumn 93, Issue , 2015, Pages 237-245

  Chae, Song Wha ^a   Woo, Sangwook ^b   Park, Jung Hyun ^a   Kwon, Youngjoo ^a   Na, Younghwa ^c   Lee, Hwa Jeong ^a  

^a Ewha Womans University   (South Korea)

^b Kolmar Korea Co Ltd   (South Korea)

^c CHA University   (South Korea)

Author keywords

Bioavailability; P glycoprotein inhibitor; Paclitaxel; Xanthone analogue; Xenograft

Indexed keywords

1 HYDROXY 5 METHOXY 3 (THIIRAN 2 YLMETHOXY) 9H XANTHEN 9 ONE; 1,3 BIS(THIIRAN 2 YLMETHOXY) 9H XANTHEN 9 ONE; 3 (2,3 DIHYDROXYPROPOXY) 1 HYDROXY 5 METHOXY 9H XANTHEN 9 ONE; 3 (2,3 DIHYDROXYPROPOXY) 1 HYDROXY 9H XANTHEN 9 ONE; 3 (3 CHLORO 2 HYDROXYPROPOXY) 1 HYDROXY 9H THIOXANTHEN 9 ONE; 3 (3 CHLORO 2 MERCAPTOPROPOXY) 1 HYDROXY 5 METHOXY 9H XANTHEN 9 ONE; 5 METHOXY 1,3 BIS(THIIRAN 2 YLMETHOXY) 9H XANTHEN 9 ONE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL; XANTHONE DERIVATIVE; XANTHONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSPORT; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ABSORPTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; INTESTINE; MCF 7 CELL LINE; METABOLISM;

ABSORPTION, PHYSICOCHEMICAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; HUMANS; INTESTINES; MALE; MCF-7 CELLS; MICE; P-GLYCOPROTEINS; RATS; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922797513     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.01.006     Document Type: Article

References (49)

1. R.L. Juliano, V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim. Biophys. Acta 455 (1976) 152-162.
2. M.M. Gottesman, Mechanisms of cancer drug resistance, Annu. Rev. Med. 53 (2002) 615-627.
3. S. Zhou, Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition, Xenobiotica 38 (2008) 802-832.
4. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, M.C. Willingham, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 7735-7738.
5. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, M.M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1, Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398.
6. A.B. Shapiro, V. Ling, Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein, Biochem. Pharmacol. 53 (1997) 587-596.
7. R. Boueer, L. Barthe, C. Philibert, C. Tournaire, J. Woodley, G. Houin, The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac, Fundam. Clin. Pharmacol. 13 (1999) 494-500.
8. J.M.M. Terwogt, M.M. Malingr-e, J.H. Beijnen, W. Wim, H. Rosing, F.J. Koopman, O. van Tellingen, M. Swart, J.H. Schellens, Coadministration of oral cyclosporin A enables oral therapy with paclitaxel, Clin. Cancer Res. 5 (1999) 3379-3384.
9. M. Fromm, P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs, Int. J. Clin. Pharmacol. Ther. 38 (2000) 69-74.
10. K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, M. Zschiesche, R. Oertel, B. Terhaag, H.K. Kroemer, W. Siegmund, Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein, Clin. Pharmacol. Ther. 68 (2000) 6-12.
11. N. Akhtar, A. Ahad, R.K. Khar, M. Jaggi, M. Aqil, Z. Iqbal, F.J. Ahmad, S. Talegaonkar, The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review, Expert. Opin. Ther. Pat. 21 (2011) 561-576.
12. S. Suksamrarn, O. Komutiban, P. Ratananukul, N. Chimnoi, N. Lartpornmatulee, A. Suksamrarn, Cytotoxic prenylated xanthones from the young fruit of Garcinia mangostana, Chem. Pharm. Bull. (Tokyo) 54 (2006) 301-305.
13. P. Kumar, R. Baslas, Phytochemical and biological studies of the plants of the genus Garcinia, Herb. Hung 19 (1980) 81-91.
14. V.V. Garcia, T.O. Magpantay, L.D. Escobin, Antioxidants potential of selected Philippine vegetables and fruits, Phili. Agric. Sci. 88 (2005) 78-83.
15. P. Devi Sampath, K. Vijayaraghavan, Cardioprotective effect of alphamangostin, a xanthone derivative from mangosteen on tissue defense system against isoproterenol-induced myocardial infarction in rats, J. Biochem. Mol. Toxicol. 21 (2007) 336-339.
16. C. Chen, Garcinone E, a xanthone derivative, has potent cytotoxic effect against hepatocellular carcinoma cell lines, Planta Med. 68 (2002) 975-979.
17. K. Matsumoto, Y. Akao, K. Ohguchi, T. Ito, T. Tanaka, M. Iinuma, Y. Nozawa, Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells, Bioorg. Med. Chem. 13 (2005) 6064-6069.
18. K. Nakatani, T. Yamakuni, N. Kondo, T. Arakawa, K. Oosawa, S. Shimura, H. Inoue, Y. Ohizumi, gamma-Mangostin inhibits inhibitor-kappaB kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells, Mol. Pharmacol. 66 (2004) 667-674.
19. B. Sundaram, C. Gopalakrishnan, S. Subramanian, D. Shankaranarayanan, L. Kameswaran, Antimicrobial activities of Garcinia mangostana, Plant Med. 48 (1983) 59-60.
20. G. Gopalakrishnan, B. Banumathi, G. Suresh, Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives, J. Nat. Prod. 60 (1997) 519-524.
21. M. Sousa, M. Pinto, Synthesis of xanthones: an overview, Curr. Med. Chem. 12 (2005) 2447-2479.
22. P. Grover, G. Shah, R. Shah, Xanthones. Part IV. A new synthesis of hydroxyxanthones and hydroxybenzophenones, J. Chem. Soc. (Resumed) (1955) 3982-3985.
23. I.K. Kostakis, N. Pouli, P. Marakos, E. Mikros, A. Skaltsounis, S. Leonce, G. Atassi, P. Renard, Synthesis, cytotoxic activity, NMR study and stereochemical effects of some new pyrano [3, 2-b] thioxanthen-6-ones and Pyrano [2, 3-c] thioxanthen-7-ones, Bioorg. Med. Chem. 9 (2001) 2793-2802.
24. S. Woo, J. Jung, C. Lee, Y. Kwon, Y. Na, Synthesis of new xanthone analogues and their biological activity testdcytotoxicity, topoisomerase II inhibition, and DNA cross-linking study, Bioorg. Med. Chem. Lett. 17 (2007) 1163-1166.
25. S. Woo, D. Kang, J. Kim, C. Lee, E. Lee, Y. Jahng, Y. Kwon, Y. Na, Synthesis, cytotoxicity and topoisomerase II inhibition study of new thioxanthone analogues, Bull. Korean Chem. Soc. 29 (2008) 471-474.
26. S. Woo, D. Kang, J.M. Nam, C.S. Lee, E. Ha, E. Lee, Y. Kwon, Y. Na, Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues, Eur. J. Med. Chem. 45 (2010) 4221-4228.
27. A. Schinkel, C. Mol, E. Wagenaar, L. Van Deemter, J. Smit, P. Borst, Multidrug resistance and the role of P-glycoprotein knockout mice, Eur. J. Cancer 31 (1995) 1295-1298.
28. M.A. Hediger, M.F. Romero, J. Peng, A. Rolfs, H. Takanaga, E.A. Bruford, The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins, Pflügers. Arch. 447 (2004) 465-468.
29. S. Choudhuri, C.D. Klaassen, Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters, Int. J. Toxicol. 25 (2006) 231-259.
30. R. Milroy, A randomized clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer, Br. J. Cancer 68 (1993) 813-818.
31. D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Faccini, M.J. Goudier, I. Krakowski, G. Netter-Pinon, M. Frenay, C. Gousset, F.N. Marie, M. Benmiloud, F. Sturtz, Verapamil increases the survival of patients with anthracyclineresistant metastatic breast carcinoma, Ann. Oncol. 11 (2000) 1471-1476.
32. A.F. List, K.J. Kopecky, C.L. Willman, D.R. Head, D.L. Persons, M.L. Slovak, R. Dorr, C. Karanes, H.E. Hynes, J.H. Doroshow, M. Shurafa, F.R. Appelbaum, Benefit of cyclosporine modulation of drug resistance in patients with poorrisk acute myeloid leukemia: a Southwest Oncology Group study, Blood 98 (2001) 3212-3220.
33. C. Erlichman, M. Moore, J.J. Thiessen, I.G. Kerr, S. Walker, P. Goodman, G. Bjarnason, C. DeAngelis, P. Bunting, Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin, Cancer Res. 53 (1993) 4837-4842.
34. A. Tolcher, K. Cowan, D. Solomon, F. Ognibene, B. Goldspiel, R. Chang, M. Noone, A. Denicoff, C. Barnes, M. Gossard, Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer, J. Clin. Oncol. 14 (1996) 1173-1184.
35. M. Sababi, O. Borgå, U. Hultkvist-Bengtsson, The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats, Eur. J. Pharm. Sci. 14 (2001) 21-27.
36. E. Chieli, N. Romiti, F. Cervelli, R. Tongiani, Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes, Life Sci. 57 (1995) 1741-1751.
37. T. Ikegawa, H. Ohtani, N. Koyabu, M. Juichi, Y. Iwase, C. Ito, H. Furukawa, M. Naito, T. Tsuruo, Y. Sawada, Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cell, Cancer Lett. 177 (2002) 89-93.
38. S.W. Chae, A.-R. Han, J.H. Park, J.Y. Rhie, H.-J. Lim, E.-K. Seo, H.J. Lee, In vitro and in vivo evaluation of phenylbutenoid dimers as inhibitors of P-glycoprotein, J. Nat. Prod. 76 (2013) 2277-2281.
39. K. Lee, S.W. Chae, Y. Xia, N.H. Kim, H.J. Kim, S. Rhie, H.J. Lee, Effect of Coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel, Eur. J. Pharmacol. 723 (2014) 381-388.
40. S. Drori, G.D. Eytan, Y.G. Assaraf, Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability, Eur. J. Biochem. 228 (1995) 1020-1029.
41. R.A. Shilling, H. Venter, S. Velamakanni, A. Bapna, B. Woebking, S. Shahi, H.W. van Veen, New light on multidrug binding by an ATP-binding-cassette transporter, Trends Pharmacol. Sci. 27 (2006) 195-203.
42. M.M. Gottesman, I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62 (1993) 385-427.
43. M.V. Varma, Y. Ashokraj, C.S. Dey, R. Panchagnula, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement, Pharm. Res. 48 (2003) 347-359.
44. P. Ramesh, Pharmaceutical aspects of paclitaxel, Int. J. Pharm. 172 (1998) 1-15.
45. J.S. Woo, C.H. Lee, C.K. Shim, S.-J. Hwang, Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031, Pharm. Res. 20 (2003) 24-30.
46. J. Kwak, S.H. Lee, G.S. Lee, M.S. Kim, Y. Ahn, J.H. Lee, S.W. Kim, K.H. Kim, M.G. Lee, Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel, Eur. J. Pharmacol. 627 (2010) 92-98.
47. S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S. Wan Kim, M.H. Seo, In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy, J. Control. Release 72 (2001) 191-202.
48. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst. 82 (1990) 1107-1112.
49. W.G. Harker, B.I. Sikic, Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line MES-SA, Cancer Res. 45 (1985) 4091-4096.